- Key Publications
The Queen Elizabeth Hospital (TQEH) Clinical Pharmacology Unit was the first hospital pharmacology unit in Australia, and now provides both a routine diagnostic clinical service and an active medical research program affiliated with the Discipline of Pharmacology at The University of Adelaide. Our aim is, wherever possible, to combine both clinical service and basic research, so as to translate new research findings into new laboratory and clinical skills that contribute to state-of-the-art clinical care of patients.
Led by Associate Professor Betty Sallustio, the Unit’s research group focuses on the areas of heart disease, kidney transplantation and cancer. We aim to individualise drug therapy through the use of therapeutic drug monitoring, particularly of immunosuppressant drugs used in kidney transplantation and the anti-anginal agent perhexiline in cardiac care. Through research in these fields we strive to provide a better understanding of drug action, metabolism and disposition in patients with varied genetic makeup in order to better use these agents and tailor them to each individual, and to develop new therapies.
Professor Betty Sallustio
Position: Principal Medical Scientist
Phone: +61 8 8222 6510
UoA: Betty Sallustio
Additional Staff Members
|Bron Lett||Research Officer|
|Fiona Wicks||Senior Technical Officer|
|Catherine DeNichilo||Technical Officer|
|Denise Dinnow||Technical Officer|
|Zac Bowden||Technical Officer|
|Name||Degree||Year Awarded||Thesis title||Supervisors|
|Dr Zaipul Md Dom||PhD, The University of Adelaide||2017||Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney||Sallustio BC, Somogyi AA, Coller JK|
|Dr Cher-Rin Chong||PhD, The University of Adelaide||2017||A pharmacological approach towards myocardial protection: new perspectives in acute and chronic cardiac disease||Horowitz JD and Sallustio BC|
|Dr John Licari||PhD, The University of Adelaide||2013||The stereoselective pharmacodynamics of the enantiomers of perhexiline||Sallustio BC, Somogyi AA and Milne RW|
Altered cellular energy metabolism is an underlying feature of both heart disease and cancer. In heart disease, maladaptive changes in energy utilisation and storage contribute to a decline in myocardial function and structural remodelling. In cancer cells, changes in energy utilisation allow increased cell survival, replication and metastasis. In addition, some cancer chemotherapy agents cause myocardial damage. Therefore, it is possible that drugs designed for treatment of heart disease, may also be useful adjunct therapies in cancer.
The success of kidney transplantation depends largely on preventing rejection of the new organ, using a combination of immunosuppressant drugs. These drugs have narrow therapeutic indices and can cause renal, gastrointestinal or haematological toxicity. Due to significant variability in their elimination from the body, doses are currently individualised by targeting therapeutic concentrations in the blood. Despite this, rejection and toxicity still occur. Our research focuses on understanding immunosuppressant distribution into lymphocytes (the mediators of rejection) and renal tissue (a major site of toxicity), as a means of better predicting individual risk of rejection and damage to the transplanted organ.
Please visit the PUBLICATIONS page on Associate Professor Betty Sallustio’s University of Adelaide Researcher Profile.
March 2014: Provisional patent application: “New Indications for (-)-Perhexiline”. BC Sallustio, G Licari, P Milner, P Druzgula
September 2013: Uses of (-)-Perhexiline. International Patent Corporation Treaty (PCT) Patent Application #PCT/AU2013/001008 (Filed 5 September 2013).
September 2012: Sallustio BC, Milne RW, Licari G and Somogyi AA. Use of Enantiomers of Perhexiline. Provisional Patent Application #2012903850, Australia (Lodged Sep 5, 2012).
September 2012: Sallustio BC, Milne RW, Licari G and Somogyi AA. Use of Enantiomers of Perhexiline. Provisional Patent Application #61697214, USA (Lodged Sep 5, 2012).
Funding since 2012
|Chief Investigators||Granting Body||Project Title||Total Grant Amount||Funding Period|
|BC Sallustio, A Evdokiou, JD Horowitz,||NHMRC – Project Grant (APP1145776)||Prevention of heart damage during anthracycline cancer chemotherapy||$327,214||2018-2020|
|AA Somogyi, BC Sallustio, JK Coller, M Hutchinson, D Barratt||The University of Adelaide - Pharmacology Equipment Round||Ultra high performance liquid chromotography - tandem mass spectrometer||$302,000||2017
|BC Sallustio, A Evdokiou, JD Horowitz||Cancer SA – Beat Cancer Project||Prevention of heart damage during anthracycline cancer chemotherapy||$75,000||2016
|BC Sallustio||Adelaide Research and Innovation (ARI), Commercial funding from Heat Metabolics Ltd.||$150,000||2014-2015
|BC Sallustio, JD Horowitz, JA Kennedy, MP Frenneaux||National Heart Foundation - Grant-in-aid||Utility of (+)- and (-)-perhexiline as model compounds for the development of new myocardial metabolic agents||$130,000||2012-2013|
|Professor John Horowitz, Leader Cardiovascular Pathophysiology and Therapeutics Group||Basil Hetzel Institute, The Queen Elizabeth Hospital||Adelaide||Australia|
|Professor Andreas Evdokiou, Leader Breast Cancer Research Unit||Basil Hetzel Institute, The Queen Elizabeth Hospital||Adelaide||Australia|
|Professor Andrew Somogyi, Dr Janet Coller, Dr Daniel Barratt||The University of Adelaide||Adelaide||Australia|
|Dr Robert Carroll, Dr Shilpa Jesudason||Royal Adelaide Hospital||Adelaide||Australia|
|Dr Melanie Madhani||Institute of Cardiovascular Sciences, University of Birmingham||Birmingham||United Kingdom|
|Professor Michael Frenneaux||Norwich Medical School, University of East Anglia||Norwich||United Kingdom|
|Dr Cher-Rin Chong||University of Oxford||Oxford||United Kingdom|